ClinicalTrials.gg
CompletedNCT03974113ATLAS-PEDSUpdated Sep 28, 2026

Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

A Phase 2/3 interventional study of Fitusiran in Hemophilia, sponsored by Genzyme, a Sanofi Company. Completed at 16 sites in 6 countries. Open to male participants aged 1 Year to 11 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 2/3, Interventional, and Treatment

Updated Sep 28, 2026Design changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
1 Year to 11 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing fitusiran in Hemophilia A — 2 open to participants now, 3 under way, 2 of them phase 3. fitusiran · Hemophilia A.

Enrollment
9th of 10
32 · median 70
Started
2020
the only one that year
Phase 2/3
Only one
of the 10
Registered
7th of 10
by date
Lead sponsor
6 of 10
Genzyme, a Sanofi Company

Among the 10 studies testing fitusiran in Hemophilia A, this one is the 9th largest by enrollment, is the only one that started in 2020, is the only one in phase 2/3, and was the 7th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

2 of the 10 studies testing fitusiran in Hemophilia A are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fitusiran

fitusiran: first FDA approval 2025 (QFITLIA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 1 Year to 11 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing fitusiran in Hemophilia A, or all of them as a file.
02

Study summary

Primary Objective:

- To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to \<12 years of age) with severe hemophilia A or B

Secondary Objectives:

  • To characterize the safety and tolerability
  • To determine fitusiran plasma concentrations at selected time points
Read the detailed description

The estimated total time on study is up to 256 weeks for participants who roll over into the extension study and up to 280 weeks for participants who do not roll over into the extension study (due to the requirement for up to an additional 6 months of follow-up for monitoring of AT levels).

03

Conditions studied

  • Hemophilia

Browse trials for

04

Who can participate

Ages eligible
1 Year to 11 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male, aged 1 to \<12 years at the time of enrollment.
  • Severe hemophilia A or B (Factor VIII (FVIII) \<1% or Factor IX (FIX) ≤2%)
  • Participants must have inhibitory antibodies to FVIII or FIX and must meet one of the following Nijmegen-modified Bethesda assay results criteria:

    • Inhibitor titer of ≥0.6 BU/mL at screening, OR
    • Inhibitor titer of \<0.6 BU/mL at screening with medical record evidence of 2 consecutive titers ≥0.6 BU/mL, OR
    • Inhibitor titer of \<0.6 BU/mL at screening with medical record evidence of 1 inhibitor titer ≥0.6 BU/mL and a history of anamnestic response or severe allergic reaction (anaphylaxis or nephrotic syndrome)
  • Adequate peripheral venous access, as determined by the Investigator, to allow the blood draws required by the study protocol
  • Weight requirements at the time of enrollment: 8 to \<45 kg
  • Willing and able to comply with the study requirements and to provide signed written obtained from parent(s)/legal guardian (hereinafter the "parent") and written or oral assent obtained from participant, per local and national requirements

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Known co-existing bleeding disorders other than hemophilia A or B
  • Antithrombin (AT) activity \<60% at Screening
  • Co-existing thrombophilic disorder
  • liver disease
  • Active virus infection
  • Acute or chronic virus infection
  • Acute Hepatitis A or hepatitis E infection
  • positive with a of \<400 cells/μL
  • History of arterial or venous thromboembolism, unrelated to an indwelling venous access
  • Inadequate renal function
  • History of multiple drug allergies or history of allergic reaction to an oligonucleotide or N-Acetylgalactosamine (GalNAc)
  • Subjects with central or peripheral indwelling catheters, with history of venous access complications leading to hospitalization and/or systemic anticoagulation therapy.
  • History of intolerance to subcutaneous (SC) injection(s)
  • Use of emicizumab (Hemlibra®) within 6 months prior to screening
  • Any other conditions or comorbidities that would make the patient unsuitable for enrollment or could interfere with participation in or completion of the study, per Investigator judgment

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Fitusiran

    Participants will receive a selected dose of fitusiran at regular intervals, as per study protocol

    Drug: Fitusiran

Interventions

  • Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous

    Also known as: SAR439774

06

What researchers measure

Primary outcomes

  1. Plasma antithrombin (AT) activity levels

    Characterize the AT activity at the optimal therapeutic dose

    Time frame: Day 1 to the AT analysis time point at the optimal therapeutic dose (approximately 256 weeks)

Secondary outcomes

  1. Number of participants reported with adverse events

    Number of participants reported with treatment-emergent adverse events (TEAEs)

    Time frame: Up to 280 weeks (up to 256 weeks of treatment + up to 24 weeks of AT follow up)

  2. Fitusiran plasma concentrations

    Plasma samples will be collected for measurement of plasma concentrations of fitusiran at specific time points post dose on Day 1 and pre dose on Day 85

    Time frame: Day 1 and Day 85

07

Study locations

16 sites
  • Children's Hospital Los Angeles Site Number : 8400002
    Los Angeles, California 90027, United States
  • Hackensack University Medical Center- Site Number : 8400008
    Hackensack, New Jersey 07601, United States
  • University Hospitals of Cleveland- Site Number : 8400007
    Cleveland, Ohio 44106, United States
  • Penn State Milton S. Hershey Medical Center- Site Number : 8400006
    Hershey, Pennsylvania 17033, United States
  • Investigational Site Number : 1240001
    Hamilton, Ontario L8N 3Z5, Canada
  • Investigational Site Number : 1240002
    Ottawa, Ontario K1H 8L1, Canada
  • Investigational Site Number : 3560006
    Bangalore, 560034, India
  • Investigational Site Number : 3560002
    Mumbai, 400 022, India
  • Investigational Site Number : 3560001
    Pune-411011, 411 011, India
  • Investigational Site Number : 3560004
    Vellore, 632004, India
  • Investigational Site Number : 3800002
    Florence, 50134, Italy
  • Investigational Site Number : 3800001
    Milan, 20122, Italy
  • Investigational Site Number : 7240002
    Madrid, Madrid, Comunidad de 28046, Spain
  • Investigational Site Number : 7920001
    Adana, 01130, Turkey (Türkiye)
  • Investigational Site Number : 7920002
    Istanbul, 34093, Turkey (Türkiye)
  • Investigational Site Number : 7920003
    Izmir, TR-35100, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Aug 2026, 78 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2019
First posted
Jun 4, 2019
StartActual
Jan 28, 2020
Primary completionActual
Aug 4, 2026
CompletionActual
Aug 4, 2026
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Design
Added Phase 2
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Design Added Phase 2

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03974113
Responsible party
Sponsor
First posted
Jun 4, 2019
Start date
Jan 28, 2020
Primary completion
Aug 4, 2026
Completion
Aug 4, 2026
Last update
Sep 28, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fitusiran

Start the discussion